Heptavalent Pneumococcal Conjugate Vaccine (Prevnar)

A pneumococcal vaccine which contains 7 pneumococcal serotypes (6B, 14, 19F, 23F, 18C, 4, 9V), each conjugated individually to the outer membrane protein complex of NEISSERIA MENINGITIDIS.

Also Known As:

Prevnar; Prevenar; 7-valent PncOMPC vaccine; PCV7 vaccine; PNCRM7; Seven-Valent Pneumococcal PS-Meningococcal OMPC Conjugate Vaccine; 7 valent PncOMPC vaccine; PncOMPC vaccine, 7-valent; Seven Valent Pneumococcal PS Meningococcal OMPC Conjugate Vaccine

Networked: 218 relevant articles (16 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Combined Vaccines: 2170
      - Heptavalent Pneumococcal Conjugate Vaccine: 218
    - Bacterial Vaccines: 529
      - Streptococcal Vaccines: 12
        Pneumococcal Vaccines: 2006
        Heptavalent Pneumococcal Conjugate Vaccine: 218

Experts

1.	Principi, Nicola: 6 articles (01/2016 - 06/2003)
2.	Mason, Edward O: 6 articles (07/2013 - 12/2004)
3.	Esposito, Susanna: 5 articles (01/2016 - 06/2003)
4.	McGowan, Karin L: 5 articles (12/2013 - 04/2003)
5.	Shah, Samir S: 5 articles (03/2011 - 04/2003)
6.	Farley, Monica M: 4 articles (09/2017 - 01/2002)
7.	Cohen, R: 4 articles (08/2009 - 07/2004)
8.	O'Brien, Katherine L: 4 articles (03/2009 - 08/2003)
9.	Santosham, Mathuram: 4 articles (03/2009 - 08/2003)
10.	Lewis, Edwin: 4 articles (09/2006 - 09/2002)

Related Diseases

1.	Pneumococcal Infections 01/01/2015 - "Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. " 08/01/2004 - "More than 95% of infants had antibody titer > or = 0.15 microg/mL of all serotypes, and 93% (serotype 23F) to 100% (serotypes 4 and 19F) of infants achieved an antibody titer > pr = 1 microg/mL. Inoculation with the heptavalent pneumococcal conjugate vaccine including the prevalent serotypes in Taiwan is safe and effective in preventing pneumococcal disease in Taiwanese children." 01/01/2002 - "Data from a large, randomized, double-blind study conducted in California (US) have confirmed the protective efficacy of PNCRM7 against invasive pneumococcal disease (e.g. " 10/01/2008 - "The heptavalent pneumococcal conjugate vaccine (PCV7) has decreased the incidence of pediatric invasive pneumococcal disease (IPD) in the United States. " 04/01/2006 - "The heptavalent pneumococcal conjugate vaccine (PCV7) has decreased the incidence of invasive pneumococcal disease among children in the United States. "
2.	Otitis Media 09/01/2006 - "Persistence of this trend will produce a significant reduction of the otitis media burden and further enhance the cost-effectiveness of heptavalent pneumococcal conjugate vaccine." 01/01/2015 - "Although children vaccinated with heptavalent pneumococcal conjugate vaccine (PCV) had fewer episodes of acute otitis media (AOM), this trial was unable to prove a simultaneous decrease in nasopharyngeal carriage. " 11/01/2008 - "This study sought to determine the microbiology of recurrent acute otitis media (AOM) and AOM treatment failure (AOMTF) in the context of widespread use of heptavalent pneumococcal conjugate vaccine (PCV7). " 11/01/2007 - "The more widely documented shift in the causative pathogens of acute otitis media (AOM) following the release of the heptavalent pneumococcal conjugate vaccine (PCV7) has also been documented in two studies of ABS in children. " 04/01/2007 - "In this study we estimated the effect of routine childhood immunization with heptavalent pneumococcal conjugate vaccine on frequent otitis media (3 episodes in 6 months or 4 episodes in 1 year) and pressure-equalizing tube insertions. "
3.	Pneumonia (Pneumonitis) 01/01/2013 - "This study quantifies the impact of Heptavalent-Pneumococcal Conjugate Vaccine (PCV7) in Panama on indigenous children younger than 5 years old, based on clinical pneumonia cases. " 09/01/2010 - "The objective of this study was to determine if the incidence of complicated pneumonias in total and due to different pneumococcal serotypes has changed following the introduction of routine immunization with heptavalent pneumococcal conjugate vaccine (PCV7). " 07/01/2010 - "This study was performed to estimate the effect of heptavalent pneumococcal conjugate vaccine (PCV7) on the pneumonia admission rate in children younger than 5 years of age, after the introduction of routine 2+1 dose schedule immunization. " 09/01/2015 - "Epidemiology of Community-Acquired Pneumonia Hospitalizations and Associated Complications Before and After the Implementation of the Heptavalent Pneumococcal Conjugate Vaccine in Athens, Greece." 04/01/2013 - "This was a retrospective case-control study on children aged 2 months to 18 years hospitalized with community-acquired pneumonia (CAP) in the pre-Prevnar era (2000-2009). "
4.	Bacteremia 07/01/2012 - "This study examined whether utilization of the Florida State Health Online Tracking System (SHOTS) immunization registry to determine Haemophilus influenzae type B and heptavalent pneumococcal conjugate (PCV7) vaccine status impacts the protocolized decision to perform a screening blood draw for occult bacteremia (OB) in young children. " 04/01/2003 - "Six (75%) of 8 cases of S pneumoniae bacteremia were caused by serotypes included in the current heptavalent pneumococcal conjugate vaccine, which was not available at the time of this study. " 08/01/2001 - "As indicated by the results of this study, the heptavalent pneumococcal conjugate vaccine may prevent the majority of occult pneumococcal bacteremia episodes. " 08/01/2001 - "This study was conducted to determine the serotype prevalence of Streptococcus pneumoniae isolates from children with occult bacteremia and to document the proportion that would be covered by the recently licensed heptavalent pneumococcal conjugate vaccine. " 08/01/2007 - "The introduction of vaccination with the heptavalent pneumococcal conjugate vaccine (PCV7) has produced an important decrease in the incidence of Streptococcus pneumoniae occult bacteremia (OB). "
5.	Tetanus 01/01/2014 - "Safety and immunogenicity of a toddler dose following an infant series of a hexavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b, hepatitis B vaccine administered concurrently or at separate visits with a heptavalent pneumococcal conjugate vaccine." 03/01/2007 - "Vaccination resulted in a significant increase (P < or = .05) in antibody levels to each vaccine antigen studied, with 100% of patients achieving protection against tetanus (GMC, 2.2 IU/mL; 95% CI, 1.8-2.7 IU/mL), 100% achieving protection against Hib (GMC, 8.4 microg/mL; 95% CI, 7.6-9.3 microg/mL), 100% achieving protection against measles (GMC, 2435 mIU/mL; 95% CI, 1724-3439 mIU/mL), 100% achieving protection against meningococcus C (GMT, 1:5706; 95% CI, 1:3510-1:9272), 92% achieving protection against the 3 poliovirus serotypes, and > or = 80% achieving protection against each of the heptavalent pneumococcal conjugate vaccine-associated serotypes. " 01/01/2009 - "One study (120 children) found that when diphtheria-polio-tetanus-acellular pertussis-Haemophilus influenzae type b (DPTaP-Hib; Pentacel) and pneumococcus (Prevnar) were injected sequentially during the same office visit, observer- and parent-reported pain scores were lower when DPTaP-Hib was injected first (SMD, -0.40 and -0.57, respectively; P <or= 0.03). " 01/01/2012 - "We report the case of a 6-month-old infant who developed subcutaneous nodules at the sites of his 4- and 6-month Pentacel (DTaP/Hib/IPV, diphtheria, tetanus, acellular pertussis, Haemophilus b conjugate, and inactivated poliovirus vaccine) and 6-month Prevnar (heptavalent pneumococcal vaccine) injections. " 10/01/2014 - "The frequency of long-lasting, intensely itching subcutaneous nodules at the injection site for aluminium (Al)-adsorbed vaccines (vaccination granulomas) was investigated in a prospective cohort study comprising 4,758 children who received either a diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b vaccine (Infanrix®, Pentavac®) alone or concomitant with a pneumococcal conjugate (Prevenar). "

Related Drugs and Biologics

1.	Vaccines
2.	Heptavalent Pneumococcal Conjugate Vaccine (Prevnar)
3.	Conjugate Vaccines
4.	Proteins (Proteins, Gene)
5.	Antigens
6.	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)
7.	13-valent pneumococcal vaccine
8.	Polysaccharides (Glycans)
9.	Anti-Bacterial Agents (Antibiotics)
10.	CRM197 (non-toxic variant of diphtheria toxin)

Related Therapies and Procedures

1.	Middle Ear Ventilation (Tympanostomy)
2.	Therapeutics
3.	Injections
4.	Antibiotic Prophylaxis